Itau Unibanco Holding S.A. Intellia Therapeutics, Inc. Transaction History

Itau Unibanco Holding S.A.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$20.02 - $27.22 $16,796 - $22,837	839 New	839 $18,000
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $2,200 - $3,072	95 Added 3.05%	3,207 $97,000
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $5,343 - $7,736	169 Added 5.74%	3,112 $98,000
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $15,664 - $20,851	453 Added 18.19%	2,943 $120,000
Q1 2023 May 12, 2023	SELL	$33.3 - $44.82 $666 - $896	-20 Reduced 0.8%	2,490 $92,000
Q4 2022 Feb 09, 2023	BUY	$33.21 - $62.69 $39,486 - $74,538	1,189 Added 90.01%	2,510 $87,000
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $27,391 - $36,423	-508 Reduced 27.77%	1,321 $74,000
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $29,560 - $58,529	768 Added 72.38%	1,829 $95,000
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $932 - $1,903	16 Added 1.53%	1,061 $77,000
Q4 2021 Feb 14, 2022	BUY	$100.76 - $138.36 $75,469 - $103,631	749 Added 253.04%	1,045 $127,000
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $1,058 - $1,414	8 Added 2.78%	296 $40,000
Q2 2021 Aug 17, 2021	BUY	$60.88 - $161.91 $17,533 - $46,630	288 New	288 $47,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.